Search results for "PERCUTANEOUS CORONARY INTERVENTION"

showing 10 items of 240 documents

Apoptosis and Mobilization of Lymphocytes to Cardiac Tissue Is Associated with Myocardial Infarction in a Reperfused Porcine Model and Infarct Size i…

2017

ST-segment elevation myocardial infarction (STEMI) is the most severe outcome of coronary artery disease. Despite rapid reperfusion of the artery, acute irrigation of the cardiac tissue is associated with increased inflammation. While innate immune response in STEMI is well described, an in-depth characterization of adaptive immune cell dynamics and their potential role remains elusive. We performed a translational study using a controlled porcine reperfusion model of STEMI and the analysis of lymphocyte subsets in 116 STEMI patients undergoing percutaneous coronary intervention (PCI). In the animal model, a sharp drop in circulating T lymphocytes occurred within the first hours after reper…

0301 basic medicineAgingmedicine.medical_specialtyArticle SubjectSwinemedicine.medical_treatmentMyocardial InfarctionInfarctionApoptosis030204 cardiovascular system & hematologyBiochemistryCoronary artery disease03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineImmune systemInternal medicineAnimalsHumansMedicineLymphocytescardiovascular diseasesMyocardial infarctionlcsh:QH573-671lcsh:Cytologybusiness.industryPercutaneous coronary interventionCell BiologyGeneral MedicineT lymphocytemedicine.diseaseDisease Models AnimalTreatment Outcomesurgical procedures operative030104 developmental biologymedicine.anatomical_structureConventional PCICardiologyFemalebusinessResearch ArticleArteryOxidative Medicine and Cellular Longevity
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patie…

2014

Introduction Particularly in the setting of acute coronary syndromes, the interplay between vascular and platelet function has been postulated to have direct clinical implications. The present trial is designed to test the effect of clopidogrel, prasugrel and ticagrelor on multiple parameters of vascular function, platelet aggregation, oxidative and inflammatory stress before and up to 4 weeks after coronary artery stenting. Methods and analysis The study is designed as a three-arm, parallel design, randomised, investigator-blinded study. Patients with unstable angina or non-ST elevation myocardial infarction undergoing coronary intervention with a drug-eluting stent will be randomised to r…

1683AdultBlood PlateletsMaleTicagrelorAdenosineTiclopidineAdolescent610 MedizinCardiovascular MedicineYoung AdultPercutaneous Coronary Intervention610 Medical sciencesProtocolHumansSingle-Blind Method1506Prospective StudiesAcute Coronary Syndrome1707AgedDrug-Eluting StentsMiddle AgedClopidogrelOxidative StressTreatment OutcomePurinergic P2Y Receptor AntagonistsFemaleEndothelium VascularPrasugrel HydrochloridePlatelet Aggregation InhibitorsFollow-Up Studies
researchProduct

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, p…

2021

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-is…

Acute coronary syndromemedicine.medical_specialtyELECTRA-SIRIO 2TicagrelorClinical CardiologyPlaceboantiplatelet therapylaw.inventionacute coronary syndrometicagrelorClinical studyPercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineHumansAcute Coronary SyndromeAspirinbusiness.industryMaintenance doseGeneral Medicinemedicine.diseasede-escalationTolerabilityELECTRA-SIRIO 2 ; acute coronary syndrome ; antiplatelet therapy ; de-escalation ; ticagrelorCardiologyCardiology and Cardiovascular MedicinebusinessTicagrelorDe-escalationPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

Retinal optical coherence tomography angiography as a biomarker of acute kidney injury after acute coronary syndrome

2018

Background Contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is frequent and associated with long-term renal impairment and mortality. Retinal vessel density (RVD) measured by OCT-Angiography could reflect the global cardiovascular burden of ACS patients and thus provide a fast and non-invasive assessment of the systemic microcirculation, that may be involved in CIN occurrence. Methods Between October 2016 and March 2017, 452 ACS patients were admitted in our coronary care unit. Retinal OCT-A was performed within two days after PCI. Patients were divided in two groups, according to Acute kidney injury (AKI) occurrence (KDIGO …

Acute coronary syndromemedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyNephropathy03 medical and health sciences0302 clinical medicineInternal medicineMedicine030212 general & internal medicine[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyFramingham Risk Scorebusiness.industryAcute kidney injuryPercutaneous coronary interventionmedicine.disease3. Good health[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansConventional PCICoronary care unitCardiologyBiomarker (medicine)Cardiology and Cardiovascular Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELT…

2016

AIMS Our aim was to compare, in a large unprotected left main coronary artery (ULMCA) all-comer registry, the long-term clinical outcome after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in patients with acute coronary syndrome (ACS). METHODS AND RESULTS Of a total of 2,775 patients enrolled in the Drug Eluting Stents for Left Main Coronary Artery Disease (DELTA) multicentre registry, 379 (13.7%) patients with ACS treated with PCI (n=272) or CABG (n=107) were analysed. Baseline demographics were considerably different in the two groups before propensity matching. No significant differences emerged for…

AdultMalemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineHumansMedicineRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassStrokeAgedAged 80 and overbusiness.industryIncidence (epidemiology)Coronary StenosisPercutaneous coronary interventionDrug-Eluting StentsMiddle Agedmedicine.diseaseSurgeryStrokeTreatment Outcomemedicine.anatomical_structurePropensity score matchingConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryEuroIntervention
researchProduct

ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study.

2018

Background: The association of soluble interleukin-1 receptor-like 1 (ST2) with left ventricular (LV) remodeling is unclear in patients with a first ST-segment elevation myocardial infarction (STEMI). The objective of this work was to assess the relationship between ST2, a marker of inflammation, and cardiac magnetic resonance (CMR) imaging-derived LV remodeling after a first STEMI. Methods: We prospectively evaluated 109 patients with a first STEMI treated with primary percutaneous coronary intervention who had ST2 assessed 24 h post-reperfusion. All patients underwent CMR imaging 1 week and 6 months after STEMI. The independent associations between ST2, LV diastolic and systolic volume in…

AdultMalemedicine.medical_specialtyCardiac magnetic resonancemedicine.medical_treatmentDiastoleMagnetic Resonance Imaging Cine030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicinemedicineHumansST segmentProspective Studiescardiovascular diseases030212 general & internal medicineMyocardial infarctionVentricular remodelingEnd-systolic volumeAgedEjection fractionVentricular Remodelingbusiness.industryLeft ventricular remodelingPercutaneous coronary interventionMiddle AgedST2medicine.diseaseInterleukin-1 Receptor-Like 1 ProteinST-segment elevation myocardial infarctioncardiovascular systemCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonanceBiomarkersFollow-Up Studies
researchProduct

Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011:current status in 37 ESC countries

2014

Item does not contain fulltext AIMS: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries. METHODS AND RESULTS: A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients admitted with STEMI during 2010 or 2011. Thirty-seven ESC countries were able to provide data from existing national or regional registries. In countries where no such registries exist, dat…

AdultMalemedicine.medical_specialtyCross-sectional studymedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]PopulationCardiologyMyocardial Infarctionacute myocardial infarction610 Medicine & healthMyocardial ReperfusionPercutaneous Coronary InterventionReperfusion therapyHumansMedicineThrombolytic TherapyIn patientHospital MortalityRegistriescardiovascular diseasesMyocardial infarctioneducationAgededucation.field_of_studybusiness.industryST elevationCoronary Care UnitsPercutaneous coronary interventionThrombolysisMiddle Agedmedicine.disease3. Good healthEuropeCross-Sectional Studiessurgical procedures operativeEmergency medicineWorkforceFemaleHuman medicineMedical emergencyCardiology and Cardiovascular Medicinebusiness
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct